Teva Pharma Reaffirms FY23 Outlook - Update

(RTTNews) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.

For fiscal 2023, the company still projects adjusted earnings in a range of $2.25 to $2.55 per share on revenues between $14.8 billion and $15.4 billion.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.40 per share on revenues of $15.06 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com